Table 1.

Patients' characteristics.

						Tumor outcome
Study vaccination groups	Patient ID	Sex (F/M)	Age at study entry	AJCC tumor staging at study entry	Vaccines received	Study entry	Study end	Best response	Disease-free survival (months)	Overal survival (months)	Discontinuation reason
Group A (no IL-2)
	LAU 986	M	35	IIIA	12	NED	NED	NED	63.8	63.8
	LAU 205	M	36	IV	2	ED	PD	PD	73.6	8.5	PD
	LAU 331	M	45	IV	18	NED	NED	NED	80.5	80.5
	LAU 518	M	65	IV	9	ED	PD	PD	5.8	33.1	PD
	LAU 1280	M	59	IIIB	8	NED	PD	NED	9.4	11.4	PD
	LAU 1330	M	61	IIIC	8	NED	PD	PD	3.5	11.3	PD
	LAU 1293	F	65	IV	12	NED	NED	NED	49.9	49.9
	LAU 1286	F	31	IIIC	10	NED	NED	NED	71.6	71.6	Patient's choice
	LAU 1352	M	65	IIIC	12	NED	PD	NED	14.0	24.5
	LAU 1350	M	61	IV	6	ED	PD	PD	3.9	34.6	PD
	all patients	2/8	60 (31–65)		10 (2–18)				32.0	33.8
Group B (IL-2)
	LAU 1357	M	58	IIIB	12 + IL-2	NED	NED	NED	6.7	68.4
	LAU 1397	F	36	IIIC	8 + IL-2	NED	PD	NED	8.7	61.2	PD
	LAU 1408	M	64	IIIB	1	NED	PD	PD	1.1	2.2	Degraded health status
	LAU 1415	M	46	IV	5 + IL-2	NED	PD	NED	5.1	12.4	PD
	LAU 1417	M	67	IIIA	8 + IL-2	NED	PD	NED	8.0	55.9	PD
	LAU 466	F	65	IV	2 + IL-2	NED	NED	NED	41.3	41.3	Patient's choice
	LAU 1394	M	64	IIIC	4 + IL-2	NED	PD	PD	8.8	56.8	PD
	LAU 1402	F	59	IIIA	4 + IL-2	NED	NED	NED	49.1	49.1	Patient's choice
	LAU 1504	M	37	IV	12	NED	NED	NED	20.2	20.2
	all patients	3/6	59 (36–67)		6 (1–12)				8.7	49.1
All groups
	all patients	5/146	59 (31–67)	3-IIIA	8 (2–18)	16- ED	8 - NED	13-NED	9.4	41.3
				3-IIIB		3-ED
				5-IIIC		0-PD	11-D	6-PD
				8-IV

Abbreviations: AJCC, American Joint Committee on Cancer; NED, no evidence of disease; ED, evidence of disease; PD, progressive disease.

^*The patient was rendered tumor-free by resection of a left axillary metastasis, after V6.